Fig 1.
Cystamine inhibits fibrin crosslinking.
Representative western blots and densitometry analysis showing the effects of cystamine (A, B) and T101 (C, D) on fibrin formation and crosslinking. Plasma was clotted by re-calcification and addition of lipidated tissue factor in the presence of cystamine or T101. Samples were reduced, boiled and separated by SDS-PAGE and identified by western blotting with anti-fibrinogen polyclonal antibody. MWM, molecular weight marker. NPP, un-clotted normal-pooled plasma. The upper high MW band (indicated by asterisk on the blot) was used for densitometry analysis of this species.
Fig 2.
Cystamine inhibits plasma clot formation.
Plasma clot formation was triggered by re-calcification and addition of lipidated tissue factor, in the presence of cystamine. Clot formation was monitored by turbidity. The data are representative of four experiments.
Table 1.
Clot formation and thrombin generation parameters.
Fig 3.
Cystamine inhibits thrombin generation.
Plasma thrombin generation was triggered by re-calcification and addition of tissue factor and phospholipids, in the presence of cystamine. Thrombin generation was monitored by calibrated automated thrombography. The data are representative of four experiments.
Fig 4.
Cystamine inhibits the amidolytic activity of coagulation enzymes.
Factors IXa (circles), Xa (squares), VIIa (diamonds), XIa (triangles), and thrombin (inverted triangles) amidolytic activity were assayed by incubating enzymes with cystamine (A) or T101 (B) and measuring the cleavage rate of chromogenic substrates. The data show means of 2–3 experiments per enzyme.